30 results about "Clostridium difficile" patented technology

Provided is a growth inhibitor for Clostridioides difficile. A growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. Also provided are a parenteral pharmaceutical preparation, a bactericide, a disinfectant, an antibacterial agent, a sanitizer or a detergent for inhibiting the growth of Clostridioides difficile.

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

To provide: an antimicrobial composition containing hydrogen peroxide that has increased efficacy against microorganisms and has no unpleasant odor; a wiping product; a method for disinfecting a hard surface; and an antimicrobial composition precursor.SOLUTION: An antimicrobial composition comprises: a hydrogen peroxide source; and a peroxide adjuvant, the peroxide adjuvant comprising an organic acid and / or salt thereof having a pKa from about 1 to about 6, the antimicrobial composition being free of acetic acid. The peroxide adjuvant is present in the composition in an amount sufficient for the composition to achieve at least 3 log10 reduction after a three minute contact time when tested against Clostridium difficile according to ASTM Test Methods E2197-11 and E2839-11.SELECTED DRAWING: Figure 1

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and / or toxin B.

The present invention provides isolated Clostridium difficile binary toxin antibodies that are capable of neutralizing binary toxin with high potency, polypeptides and nucleic acids encoding the same, and methods of use thereof.

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.

This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

A method of manufacturing ostrich antibodies may include immunizing mature female ostriches with a mixture solution comprising Clostridium difficile toxin A and toxin B, obtaining eggs from the immunized ostriches, and purifying egg yolk antibodies from the eggs.

This invention discloses a trace element composition and its application for improving the fermentation efficiency of *Clostridium autoethanogenum* under conditions containing CO2 and H2 syngas, belonging to the field of microbial fermentation technology. The trace element composition comprises the following components: 1.5% nitroglycerin, 3% magnesium sulfate, 0.5% manganese sulfate, 0.1% ferrous sulfate, 0.18% cobalt sulfate, 0.1% calcium chloride, 0.18% zinc sulfate, 0.01% copper sulfate, 0.02% potassium aluminum sulfate, 0.01% boric acid, 0.01% sodium molybdate, 0.03% nickel chloride, and 0.004% sodium tungstate. Using the trace element composition of this invention, after 4 days of fermentation under conditions containing CO2 and H2 syngas (CO2:H2=1:2, CO-free), the cell concentration is nearly twice that of the control group without the composition, and the syngas utilization rate is significantly improved. This invention provides an effective technical solution to the problem of low fermentation efficiency of self-producing ethanol Clostridium in a pure CO2 and H2 system, and has good prospects for industrial application.

The invention discloses a digital PCR (Polymerase Chain Reaction) joint detection method for four virulence related genes (tcdA, tcdB, tcdC and cdtB) of clostridium difficile and a kit thereof. The detection system comprises a specific primer pair as shown in SEQ ID NO: 1-13 and a fluorescence labeling probe group. Through a digital PCR technology platform, multi-target and high-sensitivity absolute quantitative detection is realized, interference of inhibitors in a sample can be effectively overcome, detection is completed within 4 hours, accurate pathogen load information is provided for clinic, and rapid diagnosis and treatment evaluation are assisted.

The present application firstly provides a cell wall anchor protein truncated Cwp66 which significantly improves the expression efficiency of exogenous proteins while retaining the cell wall anchoring function, resulting in unexpected technical effects. On this basis, the present application provides a cell wall protein display system which, when the bottom strain is non-toxic Clostridium difficile, exhibits excellent expression performance and colonization ability in the intestinal anaerobic environment, significantly better than the prior art. Further, the present application also provides a cell surface display system with non-toxic Clostridium difficile as the bottom strain, a recombinant strain displaying effector proteins on the cell wall surface; and its application in anti-tumor. The engineering strain not only realizes the efficient expression and display of effector proteins on the cell wall surface of Clostridium difficile, but also has excellent expression performance and colonization ability in the intestinal anaerobic environment, and can significantly inhibit the growth of tumors in a mouse model, providing a new idea for the treatment of colorectal cancer, and having important social significance and market value.

The invention provides a cascade amplification method based on Zn < 2 + > doped WOX nano-enzyme and application of the cascade amplification method in clostridium difficile toxin B detection, and relates to the technical field of lateral flow immunoassay. The cascade amplification method comprises the following steps that firstly, Zn / WOX at Au with reductase-like activity is subjected to immunochromatography to generate an initial colorimetric signal; and Zn / WOX (at) Au (at) Pt with peroxidase-like activity is formed through in-situ light-induced deposition of Pt to amplify a colorimetric signal, and then enzymatic color development is performed, so that the technical problem that clostridium difficile toxin B is difficult to quickly and highly sensitively detect in the prior art is solved, the colorimetric signal is remarkably enhanced while the simplicity and convenience of LFIA operation are maintained, and the detection sensitivity of clostridium difficile toxin B is improved. The technical effect of high-sensitivity colorimetric LFIA detection is realized.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The inventors of the present disclosure have undergone in-depth studies and found that an antibody that binds to and inhibits the proliferation of intestinal bacteria, particularly clostridium difficile cells and other intestinal bacteria cells. The present disclosure exerts the effect of providing antibodies and antigen-binding fragments thereof that bind to enteral bacteria, in particular, clostridium difficile and other enteral bacteria, and uses thereof.

The invention discloses a non-antibiotic small-molecule inhibitor of clostridium difficile toxin B and a screening method of the non-antibiotic small-molecule inhibitor. According to the method, a plurality of broad-spectrum small-molecule inhibitors targeting all TcdB receptor binding interfaces at the same time are found through virtual screening and a multi-stage calculation strategy, and the inhibition effect of the broad-spectrum small-molecule inhibitors is verified by combining cell experiments; a lead compound and an action mechanism theoretical support are provided for development of non-antibiotic anti-CDI drugs, and a screening strategy and a screening result can also provide a theoretical basis and an experimental basis for development of a next-generation precise anti-CDI therapy.

The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.

Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum. Also described herein are compounds, formulations, and methods for inhibiting, treating, and preventing infection from a pathogenic bacterium, such as Clostridium difficile or a protist, such as Leishmania donovani.

The invention relates to the technical field of molecular biology and in-vitro diagnosis, in particular to a multiple fluorescent PCR freeze-drying reagent and a kit for detecting a clostridium difficile housekeeping gene tpi, a toxin A gene and a toxin B gene. The freeze-drying reagent comprises reaction freeze-dried powder, and the reaction freeze-dried powder is prepared by freeze-drying a reaction solution prepared from components (a)-(f): (a) a first primer pair and a first probe for detecting a clostridium difficile tpi gene; (b) a second primer pair and a second probe for detecting the clostridium difficile tcdA gene; (c) a third primer pair and a third probe for detecting the clostridium difficile tcdB gene; (d) a fourth primer pair and a fourth probe for detecting an internal standard; (e) PCR reaction components, wherein the PCR reaction components comprise hot start Taq DNA polymerase, dNTPs (deoxyribonucleoside triphosphates) and a buffer system; and (f) a freeze-drying protective agent. The optimized system in the invention ensures that the triple targets of tpi (strain identification) and tcdA / tcdB (toxin typing) can still maintain high and consistent amplification efficiency after freeze-drying and redissolving, and the sensitivity can reach 5copies / reaction.

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The present invention discloses an intestinal flora marker related to inflammatory bowel disease in children, a product and its application. The intestinal flora marker of the present invention is Streptococcus salivarius Streptococcus_ salivary ovatus Bacteroides_ovatus , Bacteroides vulgaris Bacteroides_vulgatus Clostridium aldensis Clostridium_aldenense , caries actinomycetes Schaalia_ odontolytic and Clostridium difficile Clostridioides_ difficult One or more of the above can be used to predict and diagnose inflammatory bowel disease in children. The diagnostic process is completely non-invasive and highly accurate.

The invention firstly provides a method for regulating and controlling the expression of the ermB gene by knocking out a target gene or reducing the activity / expression of a target gene sigmaV or anti-sigmaV gene. The target gene is a sigma V gene or an anti-sigma V gene. Wherein the sigma V has a nucleotide sequence as shown in SEQ ID NO: 1; the anti-sigma V has a nucleotide sequence as shown in SEQ ID NO: 2. On the basis, the invention provides a clostridium difficile engineering strain with low MLSB antibiotic resistance, and the engineering strain is constructed by knocking out a target gene sigma V gene or an anti-sigma V gene. The MLSB antibiotics comprise Macrolides (macrolides), Lcosamides (lincosamides) and Streptogramin B (streptozotocin type B), and the MLSB antibiotics comprise Macrolides (macrolides), Lcosamides (lincosamides) and Streptogramin B (streptozotocin type B). Compared with a wild strain, the clostridium difficile engineering strain reduces erm gene expression by knocking out sigma V or anti-sigma V genes, so that the drug resistance of MLSB antibiotics is remarkably reduced, the drug resistance problem of clostridium difficile is fundamentally solved, and the clostridium difficile engineering strain is expected to be applied to preparation of CDI treatment drugs, achieves a good treatment effect under the condition of low dosage of antibiotics, and has broad application prospects. The method has important social significance and wide market application prospects.

A novel vaccine and methods of preventing and treating C. difficile infection in a patient is described. The vaccine is comprised of at least a portion of receptor binding domain 2 (RBD2) protein or a protein comprising at least a portion of receptor binding domain 1 (RBD1) protein and RBD2 protein (RBD1+2) from binary toxin (CDT) of C. difficile. Administration of the vaccine, as well as anti-RBD2 or anti-RBD1+2 serum, has been shown to prevent C. difficile infection as well as treat existing infections.

The present invention relates to a vaccine formulation comprising a polysaccharide-protein conjugate of formula (I), an adjuvant comprising a pharmaceutically acceptable aluminum salt, a pharmaceutically acceptable buffer, and water; and its use in therapy, in particular for prevention and / or treatment of diseases associated with Clostridioides difficile.

The present inventors have identified an miRNA capable of greatly modulating the inflammatory response induced by Clostridium difficile. They thus propose incorporating this miRNA into a pharmaceutical composition for preventing or reducing the harmful effects of this infection on the bowels of infected patients. This microRNA is miR-27a-5p. Advantageously, this miRNA can be linked to a matrix, incorporated into particles, or conveyed by a vector. It can be administered to infected subjects for therapeutic purposes.

The present application relates to the field of in vitro diagnosis, discloses a kind of clostridium difficile antigen detection kit and preparation method thereof, kit includes combined detection card and sample processing fluid;Preparation method includes: with the phosphate buffer solution of pH 7.2~7.6 as solvent, successively add divalent metal ion chelating agent, non-specific protein blocking agent and non-ionic surfactant, prepare sample processing fluid;The capture antibody for toxin A, toxin B and glutamate dehydrogenase is fixed on nitrocellulose membrane to form T1, T2, T3 detection line and quality control line respectively, three kinds of colloidal gold labeled detection antibody are sprayed on the binding pad, and are assembled into combined detection card.The present application eliminates three kinds of interference of lipid particles, interfering proteins and divalent metal ions in fecal matrix on colloidal gold detection respectively, maintains the detection limit of toxin A at 160 pg / ml in complex fecal matrix, there is no cross interference between three targets, and the synchronous combined detection of glutamate dehydrogenase, toxin A and toxin B is completed within 15 minutes.

The invention relates to the field of microorganisms, and discloses a microbial agent for inhibiting growth of clostridium difficile and enterococcus faecalis and application of the microbial agent. The microbial agent is prepared from bifidobacterium longum, lactobacillus delbrueckii subsp. Bulgaricus, bifidobacterium breve, lactobacillus reuteri, ackermann mucilaginosus and bacteroides ovatus. The six strains in the microbial inoculum cooperate to form a thick and dense symbiotic biological membrane, the thick and dense symbiotic biological membrane is rapidly planted in a symbiotic system of clostridium difficile (CD) and enterococcus faecalis (EF), a physical barrier is constructed, and colonization and diffusion of the clostridium difficile (CD) and the enterococcus faecalis (EF) are spatially inhibited; meanwhile, the content of leucine and ornithine secreted by EF in a system is remarkably reduced through metabolism synergy, cross-breeding of the leucine and the ornithine is blocked, growth is inhibited, CD spore germination can be inhibited by 100%, CD toxin secretion is reduced, the yield of pathogenic symbiotic biological membranes is reduced, CD pathogenicity is weakened in multiple links, all-around intervention on co-infection of CD and EF is achieved, and the application prospect is wide. And an efficient and safe solution is provided for the clinical problem.